Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
Status:
Withdrawn
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies azacitidine in treating patients with triple negative stage I-IV
invasive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as
azacitidine, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing.